Effects of Aureobasidium Pullulans produced β-1,3-1,6-glucan on CA19-9, sCD44, IgA and sCD209 in patients undergoing surgical resection of malignant pancreatic tumors

• Published in: Journal of clinical oncology Vol. 42; no. 23_suppl; p. 96
• Main Authors: Tsukada, Akira, Miyajima, Isao, Uchiyama, Satomi, Tabe, Daiki, Ikewaki, Nobunao, Rajappa, Senthilkumar, Ichiyama, Koji, Iwasaki, Masaru
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 10.08.2024
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2024.42.23_suppl.96

96Background: Pancreatic cancer is a highly refractory tumor with poor prognosis, which aggressively progresses by suppressing the immunity. Surgical procedure related stress further weakens the immunity and aids cancer stem cell metastases, warranting immune enhancement strategies. AFO-202 strain of Aureobasidium Pullulans produced β-1,3-1,6 glucan (Nichi BRITE), having yielded immune enhancement in earlier studies, we evaluated its effects in patients undergoing surgical resection of malignant pancreatic tumors. Methods: 30 subjects in two groups were enrolled; control arm (n=15, "P" group) received a placebo, and treatment arm (n=15, "G" group) received Nichi BRITE 250mg/day, in three divided doses, for 22 days from the pre-operative day. Serum beta glucan specific IgA2 (BG-IgA), total IgA (IgA), sCD209, Serum Amyloid A (SAA), sCD44 and CA19-9 were evaluated at base line and at periodic intervals. Results: sCD44 significantly decreased 48.94% in "G" group and only 4.58% in "P" group (p = < 0.0001) on day 21. sCD209 on day 21 in "G" group increased by 54.68% (p = 0.04) against 15.03% in "P". BG-IgA at day 10 increased around 150% in "G", and only by 6% in "P". Total IgA, increased by 20.60% in "G" and only 5.73% in "P". SAA increased to 251.32% in "G" on day 21 and in "P" it decreased by 6.11%. Decreased sCD44 when correlated against Neutrophil to Lymphocyte Ratio (NLR), a significant positive correlation was in "G" (r statistic= 0.758; p-value =0.006; 95% CI= 0.2907~0.9335), but a negative correlation in "P". Pancreatic cancer marker CA19-9 decreased significantly in three months follow up in "G" (-86.02 U/ml) whereas it increased in "P" by +5.91 U/ml. Mean survival of Nichi BRITE group was 25.9 months against 22.3 months in "P" group. Conclusions: Administration of Nichi BRITE glucans to patients undergoing surgical resection of malignant pancreatic tumor was safe and it enhanced biomarkers of innate and adaptive immunity. Nichi BRITE significantly decreased the circulating cancer stem cell marker sCD44 implying a lesser recurrence risk, especially in patients with high NLR ratio who have a poor prognosis, and significantly reduced the CA 19-9 levels implying a better prognosis, making us recommend it as an adjuvant to patients undergoing surgeries for malignant tumors, and be included in the guidelines of clinical nutrition.